Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic Leukemia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: An individualized exercise program may be effective in lessening fatigue and depression and improving quality of life in patients undergoing chemotherapy for leukemia.
PURPOSE: This clinical trial is studying how well individualized exercise programs work in patients receiving chemotherapy for newly diagnosed acute or relapsed myeloid leukemia or lymphoblastic leukemia.
| Condition | Intervention |
|---|---|
|
Depression Fatigue Leukemia Musculoskeletal Complications Psychosocial Effects of Cancer and Its Treatment |
Behavioral: Resting vitals Behavioral: Body Composition Behavioral: Timed Get-up and Go test (TGUG). Behavioral: Cardiorespiratory assessment Behavioral: Handgrip evaluation Behavioral: Dynamic muscular endurance |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Supportive Care |
| Official Title: | In-Hospital Individualized Prescriptive Exercise Intervention for Acute Leukemia Patients Undergoing Chemotherapy |
- Effects of an individualized prescriptive exercise intervention [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]All patients will participate in an individualized prescriptive exercise intervention 3 to 4 times per week (depending on the physical status of each patient during each week) for a period of 6 weeks. The exercise intervention will begin on week 1 of the study, the day after the first battery of initial assessments is concluded. Each exercise session will be divided into two bouts. One bout will be administered in the morning and the second one late in the afternoon
- Number of subjects experiencing fatigue, depression, and quality of life issues [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]The Functional Assessment of Cancer Therapy-General (FACT-G) will be administered to assess the levels of fatigue, and quality of life on weeks 2, 3 and 5 of the 6 week trial. The Center for Epidemiologic Studies Depression Scale (CES-D) will be also administered to explore the effects of exercise on depression on weeks 2, 3 and 5 of the 6 week trial.
| Enrollment: | 10 |
| Study Start Date: | February 2006 |
| Study Completion Date: | August 2009 |
| Primary Completion Date: | January 2007 (Final data collection date for primary outcome measure) |
-
Behavioral: Resting vitals
OBJECTIVES:
Primary
- Determine the effects, in terms of fitness and blood parameters, fatigue levels, and quality of life, of an individualized prescriptive exercise intervention in patients with newly diagnosed acute or relapsed myeloid or lymphoblastic leukemia undergoing chemotherapy.
Secondary
- Determine the feasibility of developing an exercise program for these patients.
- Assess the changes in cardiovascular endurance, muscular strength, selected blood parameters, and response of inflammatory proteins to exercise in these patients.
- Evaluate fatigue, depression, and quality of life of these patients.
OUTLINE: This is a pilot study.
Patients participate in an individualized prescriptive exercise intervention 3 to 4 times per week for 6 weeks (4 weeks in hospital, 2 weeks at home). Exercise begins concurrently with the first course (induction therapy) of chemotherapy. Each exercise session consist of 3-5 minutes of light stretching (stretching component), 5-10 minutes of cycling on the recumbent bicycle (cardiorespiratory component), 5-15 minutes of resistance training including hand dumbbells, exercise tubing, rubber bands, and fit balls (resistance training component), and 5-10 minutes of abdominal exercises (core muscles component).
Quality of life, fatigue, and depression are assessed at baseline and weekly during study intervention.
Blood samples are collected at baseline and at weeks 3 and 6 for cytokine analysis.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Newly diagnosed acute or relapsed myeloid or lymphoblastic leukemia
- Currently receiving re-induction therapy or designated for chemotherapy treatment
- Expected hospital stay of 3-4 weeks or longer
- Participation in the study must be approved by the physician directly responsible for the patient's care while at University of North Carolina Hospitals
PATIENT CHARACTERISTICS:
No condition that would compromise the patient's ability to participate in the exercise rehabilitation program, including any of the following:
- Immune deficiency
- Acute or chronic bone, joint, or muscular abnormalities
- Acute or chronic respiratory disease
- Cardiovascular disease
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Contacts and Locations| United States, North Carolina | |
| Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill | |
| Chapel Hill, North Carolina, United States, 27599-7295 | |
| Principal Investigator: | Claudio L. Battaglini, PhD | UNC Lineberger Comprehensive Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | UNC Lineberger Comprehensive Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00499759 History of Changes |
| Other Study ID Numbers: | LCCC 0526, CDR0000551972 |
| Study First Received: | July 10, 2007 |
| Last Updated: | March 5, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by UNC Lineberger Comprehensive Cancer Center:
|
fatigue depression psychosocial effects of cancer and its treatment musculoskeletal complications acute undifferentiated leukemia adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) |
adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) untreated adult acute lymphoblastic leukemia untreated adult acute myeloid leukemia recurrent adult acute myeloid leukemia secondary acute myeloid leukemia recurrent adult acute lymphoblastic leukemia |
Additional relevant MeSH terms:
|
Depression Depressive Disorder Fatigue Leukemia Leukemia, Lymphoid Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Myeloid Behavioral Symptoms Mood Disorders |
Mental Disorders Signs and Symptoms Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013